DNM2 and autosomal dominant centronuclear myopathy: Based on these findings, a phase I/II, dose escalation trial testing the molecule DYN101 (an ASO directed against human DNM2 RNA), was performed on patients affected by XLMTM and DNM2 centronuclear myopathies.